Cholesterol-lowering Drug Market Size, Share, Growth Report 2030

Global Cholesterol-lowering Drug Market: Overview

Cholesterol belongs to the group of steroids. These are organic molecules and a kind of lipids. Cholesterol is a vital structural component and membrane of animal cells. However, it is biosynthesized by all animal cells. The importance of cholesterol is the biological synthesis of steroids hormones like testosterone & estrogen, vitamin D, and bile acid. Most of the cholesterol production happens in poultry, meat, eggs, and dairy products. Moreover, the high level of cholesterol can be the side effects of genetic disease, obesity, unhealthy diet, and other diseases.

Report Scope:

Global Cholesterol-lowering Drug Market: Growth Factors

The foremost factor driving the global cholesterol lowering drug market is the increasing awareness regarding bad cholesterol. This growth has induced the manufacturers to go through intensive investigational studies to find out the well-tolerant drugs in the patients to improve the results. Moreover, the extensive research and development activities in the sector and incorporation of the bempedoic acid for developing the new drugs are fueling the growth of the global cholesterol lowering drug market.

The emergence of the new drug classes for the goodness of non-statin users is augmenting the market growth. However, a surge in the number of statin users and several guidelines recommending the adoption of antihyperlipidemic is further fueling the market growth.

High cholesterol increases the risks of stroke and myocardial infarction. The hypercholesterolemia also increases the vulnerability to CVD. Hyperlipidemia is also related to some comorbidities like chronic kidney disease and diabetes type 2. These factors further boost market growth. The emergence of therapies like bempedoic acid, PCSK9 inhibitors, and several other drugs is expected to expand the market.

To enhance cardiovascular risk assessments, manufacturers are adopting the personalized approach to get improved results in patients. However, the surging trend has led the concept of precision medicine in the market to lower cholesterol. Manufacturers are growing awareness among the consumers by showcasing the promising results of PCSK9 inhibitors for the treatments of coronary artery diseases.

The leading players in the global cholesterol lowering drug market are improving their production capacities to produce Evolocumab, used to treat high risk patients. They are also trying to manufacture Canakinumab, an antibody that helps in declining cardiovascular events. The manufacturers are concentrating on secondary prevention statins that help in lowering the LDL-C in patients. Improved outcomes of these efforts of the manufacturers are expected to boost the growth of the market globally.

Global Cholesterol-lowering Drug Market: Segmentation

The global cholesterol lowering drug market can be segmented into disease type, drug class, and region.

By disease type, the market can be segmented into hyperlipidemia, cardiovascular diseases, and hypercholesterolemia.

By drug class, the market can be segmented into the combination, PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, and statins, miscellaneous. The miscellaneous drug includes bempedoic acid, mipomersen, lomitapide, nicotinic acids, and omega-3 fatty acids.

The statins segment holds the largest share in the global cholesterol lowering drug market owing to the emergence of effective therapies like bempedoic acid and PCSK9 inhibitors.

The miscellaneous segment is also expected to grow significantly during the forecast period owing to the improved safety and surge in the adoption of such drugs by the end-users.

Global Cholesterol-lowering Drug Market: Regional analysis

Europe holds the largest share in the global cholesterol lowering drug market due to the increasing prevalence of hypercholesterolemia cases in the region. North America is among the potential regions in the global cholesterol lowering drug market due to the constant technological developments in the sector.

Asia pacific is a potential region with lucrative growth opportunities in the global market during the forecast period.

Global Cholesterol-lowering Drug Market: Competitive Players

Some of the significant players in the global cholesterol lowering drug market are Daiichi Sankyo, Merck & Co., Inc., AstraZeneca, Esperion Therapeutics and CJ Healthcare, Sanofi, Amgen, Inc., Pfizer, Inc, Merck & Co., Inc., AbbVie, Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, and GlaxoSmithKline plc.

Global Cholesterol-lowering Drug Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.